Abstract This study tested the hypothesis that optimized microneedle patch formulations can stabilize trivalent subunit influenza vaccine during long-term storage outside the cold chain and when exposed to potential stresses found during manufacturing and storage. Formulations containing combinations of trehalose/sucrose, sucrose/arginine, and arginine/ heptagluconate were successful at retaining most or all vaccine activity during storage at 25°C for up to 24 months as determined by ELISA assay. The best formulation of microneedle patches contained arginine/heptagluconate, which showed no significant loss of vaccine activity during the study. To validate these in vitro findings, mice were immunized using trivalent influenza vaccine stored in microneedle patches for more than 1 year at 25°C, which elicited antibody titers greater than or equal to fresh liquid vaccine delivered by intradermal injection, indicating the retention of immunogenicity during storage. Finally, influenza vaccine in microneedle patches lost no significant activity during exposure to 60°C for 4 months, multiple freeze-thaw cycles, or electron beam irradiation. We conclude that optimally formulated microneedle patches can retain influenza vaccine activity during extended storage outside the cold chain and during other environmental stresses, which suggests the possibility of microneedle patch storage on pharmacy shelves without refrigeration.
Background
Influenza is estimated to cause up to 5 million illnesses and 500,000 deaths each year. [1] Annual seasonal influenza vaccination is recommended by the Centers for Disease Control and Prevention [2] , and more than 148 million people received the vaccine in the USA during the 2014-2015 influenza season [3] . As a result, there is significant cost, complex logistics, and vaccine spoilage due to the need to distribute and store the vaccine in the cold chain [4] . Elevated temperatures as well as exposure to freeze-thaw cycles have been shown to adversely affect the stability of seasonal influenza vaccine [5] .
One method to maintain the activity of vaccines, or proteins in general, is lyophilization. For many proteins, preservation in a dry state enables storage for longer time or without refrigeration [6] . In a dry state, protein mobility is greatly reduced [7] , and there is less water available for many decomposition reactions [8] . Lyophilized biopharmaceuticals must still be reconstituted with an appropriate diluent and administered via a hypodermic needle and syringe. All current influenza vaccines are stored and delivered in the liquid state and also require the use of the cold chain. The cold chain can cost hundreds of million dollars per vaccine program [4] , thus an influenza vaccine stable at room temperature could be of significant financial benefit.
We and others are developing microneedle patches for vaccination against influenza and other diseases [9] [10] [11] [12] [13] [14] . Microneedle patches contain an array of sub-millimeter projections composed primarily of water-soluble sugars and polymers that encapsulate a payload of drug or vaccine [15] . Since these patches hold the vaccine in a dry state, once produced, microneedle patches can maintain stability similar to lyophilized vaccine. To achieve this stable state, formulation excipients must be optimized to maintain vaccine activity during manufacturing and subsequent storage. During manufacturing, a vaccine and excipient mixture is cast and dried into molds and allowed to dry, which can damage the vaccine. There has been work to develop formulation strategies to stabilize influenza vaccine during microneedle fabrication. For example, silk [16] and trehalose [17] have been incorporated into microneedle formulations to stabilize influenza vaccine during drying. Aside from stability enhancement, microneedles could increase the acceptance of vaccine administration [18] and improve the immune response in recipients [19, 20] .
Formulation excipients that function as lyoprotectants of proteins are often small sugars [21] [22] [23] [24] . There are thought to be two different, yet possibly simultaneous, mechanisms by which sugars and polyols maintain protein stability in a dried state [22, 23] . One is the formation of an amorphous sugar glass phase with such a high viscosity that molecular mobility is severely restricted. [25] This restricted mobility decreases kinetics of possible degradation pathways, both chemical and physical [7] . The other mechanism is the replacement of removed water molecules' hydrostatic interactions by hydroxyl groups from the sugars [26] , which is needed because water molecules form a stabilizing hydration shell around proteins in solution [27] . Polysaccharides, such as inulin [28] , and amino acids, such as arginine [29] , have also been used to stabilize proteins, due also to advantageous excipient/protein interactions and the creation of a favorable dry matrix.
In a previous study, we screened 61 different formulation excipients and some of their combinations to find three pairwise excipient combinations that were especially promising at stabilizing a trivalent subunit influenza vaccine: trehalose/sucrose, sucrose/arginine, and arginine/heptagluconate [30] . In this study, we further examined these formulations for stability at 25 and 40°C over periods up to 24 months and during environmental stresses such as exposure to 60°C for 4 months, multiple freezethaw cycles, and electron beam irradiation. 
Materials and methods

Vaccine and reagents
Formulations
Vaccine stock solutions were received in phosphate-buffered saline (PBS). To buffer exchange into ammonium acetate buffer, monovalent stock solutions of the desired strain were concentrated at least tenfold using Vivaspin centrifuge filters (Sartorius AG, Göttingen, Germany) and then diluted with 150 mM ammonium acetate buffer. This process was repeated two to three times. Finally, additional ammonium acetate buffer was used to adjust the vaccine solution to the appropriate concentration for experiments.
To formulate vaccine for casting onto molds, dry excipients were weighed and placed into type 1 glass vials (Wheaton, Millville, NJ), to which buffer-exchanged vaccine stock solution was added. All formulations contained 1 % w/v 250 kDa sodium carboxymethyl cellulose (NaCMC). All formulations contained a total stabilizing excipient concentration of 10 % w/v, where the concentration was split among up to four compounds.
Vaccine stability testing on chips
As previously described [30] , throughput of formulation screening can by increased by drying droplets of vaccine solution on surfaces representative of molds used to make microneedles. For this purpose, a thin film of polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning, Midland, MI) was cured, from which 6 mm-diameter circular chips were removed with a hammer punch. Droplets of approximately 2 μL of formulated vaccine solution were placed onto each chip. Droplet weights were measured (Sartorius SE2 Ultra Micro Balance, Sartorius AG, Göttingen, Germany) to more precisely determine the amount of solution applied. Chips were then packaged in aluminum pouches (Oliver-Tolas Healthcare, Grand Rapids, MI) and sealed with an impulse heat sealer (AIE-300, American International Electric, Industry, CA). All samples were packaged with desiccant (Hammond Drierite, Xenia, OH). Chips were then stored in environmental test chambers maintained at 40°C (model 6020, Caron, Marietta, OH).
Vaccine stability testing in microneedle patches
Microneedle patches were prepared using two different casting solutions. First, a PDMS mold in the shape of the microneedle patch was prepared, using methods described previously [31] . The vaccine casting solution consisted of influenza vaccine, 1 % w/v NaCMC, and 10 % w/v of stabilizer in 150 mM ammonium acetate buffer. The matrix casting solution consisted of polyvinyl alcohol (PVA), sucrose, and water in a mass ratio of 8:6:15. To make microneedle patches, vaccine casting solution was placed on a mold to fill the microneedle cavities with the aid of vacuum. Excess vaccine solution was removed from the mold surface with a flat blade. The vaccine casting solution was then allowed to dry into the tips of the microneedle mold cavities under vacuum. Next, matrix casting solution was placed on the mold and allowed to dry under vacuum, thereby forming a complete microneedle patch. Each patch was then stored in a desiccator at room temperature (∼21-25°C) for 2 days before demolding with Scotch tape (3 M, St. Paul, MN).
Demolded patches were packaged with desiccant in aluminum pouches and stored at a given temperature (i.e., 4, 25, or 40°C) in stability chambers. For patches subjected to freezethaw cycles, each cycle consisted of 2 h at −20°C followed by 2 h at 4°C. Patches subjected to electron-beam sterilization were irradiated using a 10-MeV (20 kW) system at room temperature for a total exposure of 10 or 20 kGy. The nonirradiated controls were subjected to the same travel and storage conditions as the test samples.
ELISA assay
Reconstituted vaccine samples were assayed for hemagglutinin activity using a sandwich enzyme-linked immunosorbent assay (ELISA). Polyclonal, strain-specific antibodies were received from the Center for Biologics Evaluation and Research of the Food and Drug Administration (Silver Spring, MD). Antibodies were conjugated to horseradish peroxidase with a Lightning-Link conjugation Kit (Innova Biosciences, Cambridge, UK). Unformulated vaccine stock was serially diluted in PBS with 0.5 % Tween-20 (PBST) and used to generate a reference standard curve. After the prescribed storage time, chips and microneedle patches were placed into PBST so that the dried vaccine and excipients were redissolved. This solution was run parallel to the reference standard curve on an Immulon 2HB 96-well microplate (Thermo Scientific, Waltham, MA). The microplate was washed three times between each step with PBST containing 3 % w/v bovine serum albumin. The horseradish peroxidase (HRP) substrate reaction involved SureBlue Reserve TMB (3, 3′,5,5′-tetramethylbenzidine) solution (KPL, Gaithersburg, MD), which was stopped with TMB Stop Solution (KPL). The microplate absorbance at 620 nm was read using an iMark plate reader (Bio-Rad, Hercules, CA). The standard curve was fit to a four-parameter function using the Microplate Manager 6 software (Bio-Rad).
Immunization of mice
Groups of female BALB/c mice (n = 8 per group), all 6-8 weeks of age, were immunized via either an intradermal (ID) injection at the base of the tail or by application of a microneedle patch to the back. In the first study, animals were vaccinated with 3.8, 2.8, and 3.8 μg of H1N1, H3N2, and B strains, respectively, administered either by ID injection of fresh stock vaccine or using microneedle patches stored at 25°C for 13 months. In the second study, animals were vaccinated with 1, 0.6, and 0.6 μg of H1N1, H3N2, and B strains, respectively, by ID injection of fresh stock vaccine, by ID injection of vaccine reconstituted from microneedle patches stored at 25°C for 13 months, or using freshly made microneedle patches. All patches were made using arginine and heptagluconate at a mass ratio of 50:50 as the stabilizers in the vaccine casting solution.
Hair was removed 1 day prior to immunization using electric clippers and a depilatory cream (Nair; Ewing, NJ). Patches were applied by pressing the patch against a pinch of hair-free skin using the thumb for 1 min. Adhesive on the patch backing held the patch in place for a further 20 min to ensure microneedle dissolution in the skin. Blood was drawn via the jugular vein at days 0, 14, and 28. Whole blood was then spun down in serum separation tubes (Becton Dickinson, Franklin Lakes, NJ) to collect the serum. All studies involving animals were approved by the Institutional Animal Care and Use Committees (IACUC) of Georgia Tech.
Hemagglutination inhibition titers
Production of influenza-specific antibodies was determined by hemagglutination inhibition (HAI) assay. Serum was treated with receptor-destroying enzyme (Denka Seiken, Tokyo, Japan) overnight at 37°C. Samples were then incubated at 56°C for 30 min before being incubated overnight with packed red blood cells at 4°C. After centrifugation, supernatant was collected, serially diluted in PBS, and mixed with separate strain-specific influenza viruses for 30 min. Finally, 0.5 % chicken red blood cells was added. The reciprocal of highest dilution titer that prevented hemagglutination was read as the HAI titer.
Electron beam irradiation
Electron beam irradiation was conducted by Synergy Health (Lima, OH) using a 10-MeV (20 kW) system that exposed microneedle patches to 10 or 20 kGy irradiation. Irradiation was conducted at ambient temperature. The non-irradiated controls were subjected to the same travel and storage conditions as the test samples.
Statistics
All statistics were calculated using Excel 2013 software (Microsoft, Redmond, WA). Reported averages represent the arithmetic mean of the tested samples, except for HAI titers, which are presented as the geometric mean titer for each group. Seropositivity was considered to be an HAI titer greater than or equal to 40. Comparisons between individual samples were performed using an unpaired Student's t-test with a significance cutoff of p < 0.05.
Results
Formulation screening to stabilize monovalent influenza vaccine
Our previous study indicated that vaccine casting solution formulations containing two-way combinations of trehalose, sucrose, arginine, and heptagluconate stabilized influenza vaccine during storage at elevated temperature [30] . We therefore studied the ability of these excipients to stabilize influenza vaccine in greater detail by screening for stability using droplets of formulated monovalent vaccine dried onto PDMS chips to represent drying on a microneedle patch mold and then stored at 40°C.
As shown in Fig. 1 , vaccine dried with no formulation stabilizers lost at least half of its activity during drying (day 0) and then lost almost all activity within 1 month of storage. The three two-way combinations of stabilizers found previously to be optimal at a mass ratio of 50:50 [30] were studied additionally at mass ratios of 90:10 and 10:90. Comparisons between 18-month activity and initial activity showed no change in vaccine stability for all of these formulations, independent of mass ratio (Fig. 1 , Student's t-test, p > 0.05). We also examined the four possible three-way combinations of these excipients as well as their four-way combination, and again found no significant change in vaccine activity after 18 months (Fig. 1, Student' s t-test, p > 0.05).
Stability of influenza vaccine patches over time at room temperature
Guided by the screening results generated on chips showing that all of the two-, three-, and four-way combinations of stabilizers effectively stabilized the vaccine, we made microneedle patches containing monovalent vaccine using the three optimal two-way combinations and tested their stability during storage at 25°C for 24 months. These patches were made by first casting a vaccine solution containing the antigen and stabilizing excipients and, after drying, casting a matrix solution containing sucrose and PVA to fill any remaining space not occupied by the dried vaccine solution and to form the patch backing. Among the microneedle patches with two-way combinations of stabilizing excipients, both the trehalose/sucrose and arginine/heptagluconate formulations exhibited no significant loss of vaccine activity after 24 months (Fig. 2 , Student's t-test, p > 0.05).
Using just the individual stabilizers showed that formulation with any of the saccharides resulted in no significant loss of vaccine activity after 24 months (Fig. 2, Student's t-test, p > 0.05) , but there was a significant decrease in vaccine activity at 24 months when arginine was used as the only stabilizer (Fig. 2 , Student's t-test, p = 0.03). The unformulated vaccine also had no loss of activity after 24 months (Fig. 2 , Student's t-test, p > 0.05). However, the patches using unformulated vaccine and vaccine formulated with the single stabilizers sucrose, arginine, or heptagluconate had significant losses in activity during fabrication on day 0 by comparison with vaccine activity in patches formulated with arginine/heptagluconate as a positive control (Fig. 2 , Student's t-test, p < 0.05). This is probably due to differences in vaccine stabilization associated with vaccine drying during patch fabrication.
Comparison of these findings in microneedle patches to the previous findings on chips indicates that the excipients in the matrix casting solution used to make the microneedle patch backing provided additional stabilization.
Based on these findings with monovalent patches, we assessed the stability of trivalent patches using the three twoway combinations of stabilizers. There was no significant change in vaccine activity for any of the three vaccine strains using the arginine/heptagluconate formulation after storage for 12 months at 25°C, as well as the H1N1 strain when formulated with trehalose/sucrose and stored for 18 months (Fig. 3, Student' s t-test, p > 0.05). There was also no noticeable change in the appearance of the patches after storage compared to freshly prepared patches (Fig. 4a, b) . These findings further indicate the superiority of the arginine/heptagluconate formulation as a stabilizer.
Immunogenicity of stored influenza vaccine patches
To determine if the in vitro vaccine stability of microneedle patches correlated with in vivo immunogenicity, mice were immunized using microneedle patches containing trivalent influenza vaccine that had been stored for 13 months at 25°C and compared to ID injection of fresh vaccine. There was no significant difference in immune response to the H1N1 influenza strain between the mice immunized with a stored microneedle patch and by an ID injection (Fig. 5a) . Immune response to the H3N2 strain was higher for stored microneedle patches than ID injection (Fig. 5b) . For both strains, all mice were seropositive after vaccination with stored microneedle patches, but only 50-70 % were seropositive after ID vaccination (Fig. 5c, d ). However, immune responses to the B strain of influenza could not be measured due to lack of access to the virus needed for the assay.
The superior immune response of stored microneedle patch vaccination compared to ID vaccination may at first be surprising. However, comparison of fresh microneedle patch vaccination to ID vaccination similarly showed improved immune response after microneedle patch vaccination (Fig. 6) , indicating that the superior response was not associated with was formulated with combinations of two, three, or four stabilizing excipients at a total stabilizer concentration of 10 % w/v in the vaccine casting solution. For the two-stabilizer combinations, the concentration ratio is shown, where the first number corresponds to the relative content of the first excipient listed below it on the x-axis. The three-way and fourway formulation had equal amounts of each excipient. T trehalose, S sucrose, A arginine, H calcium heptagluconate. HA activity is expressed as a percentage of HA activity in the liquid casting solution. Data represent averages of n = 12 replicates, with standard deviation bars shown storage, but was instead associated with the microneedle patch method of vaccination, which is consistent with prior literature [20, 32] . Moreover, ID injection of vaccine reconstituted from stored microneedle patches generated immune responses not significantly different from ID injection of fresh vaccine (Fig. 6) , further suggesting that stored vaccine was as immunogenic as fresh vaccine and that improved immunogenicity was associated with microneedle patch administration.
Stability of influenza vaccine patches at elevated temperature
While microneedle patches stored at 25°C simulate vaccine storage in a climate-controlled pharmacy or warehouse, we wanted to determine if microneedle patches remained stable at higher temperatures. Microneedle patches containing monovalent influenza vaccine were therefore stored at 60°C for 4 months. There was no significant loss of vaccine activity for these patches as a function of time (Fig. 7 , ANOVA, p > 0.05) or in comparison to patches stored in parallel at 25°C (Fig. 7 , ANOVA, p > 0.05). Visual inspection of the patches indicated minor discoloration of the patch after storage at 60°C, suggesting that patch excipients may have been affected (Fig. 4c) .
Stability of influenza vaccine patches after multiple freeze-thaw cycles
Vaccines can be exposed to freeze-thaw cycles if stored without environmental controls or during poorly controlled refrigeration. To address such conditions, microneedle patches containing monovalent influenza vaccine were subjected to five freeze-thaw cycles, alternating between −20 and 4°C, over the course of 24 h, after which there was no significant change in vaccine activity compared to patches maintained at 25°C (Fig. 8, Student' s t-test, p = 0.95). Patches maintained at 4 or at −80°C also had no significant loss of activity compared to patches stored at 25°C (Fig. 8, Student's t-test, p > 0.05) . Interestingly, unformulated liquid vaccine subjected to identical freeze-thaw cycles also showed no loss in vaccine activity (Fig. 8, Student' s t-test, p = 0.88). The appearance of patches after the freeze-thaw cycles showed no apparent differences from fresh patches (Fig. 4d) .
Stability of influenza vaccine patches after exposure to electron beam sterilization cycle
Terminal sterilization of microneedle patches could provide cost savings relative to aseptic manufacturing. Microneedle patches containing monovalent influenza vaccine were therefore subjected to electron beam sterilization at two different radiation doses. Compared to untreated patches, there was no significant loss of vaccine activity at either radiation dose (Fig. 9 , Student's t-test, p > 0.05). Patch appearance after irradiation showed no apparent changes from fresh patches (image not available).
Discussion
This work builds upon previous work that included a screen of microneedle formulation excipients to stabilize influenza vaccine [30] . The stability of dried vaccine on chips as well as in patches stored for up to 6 months at 25°C was reported in that work. The work reported here shows further evidence of stability when influenza vaccine was incorporated into dissolving microneedle patches and maintained activity after storage at 25°C for at least 24 months, 60°C for at least 4 months, five freeze-thaw cycles, and electron beam irradiation. The ability to withstand this wide array of stressful conditions suggests that a properly formulated microneedle patch could enable influenza vaccine to be removed from the cold chain. Resistance to electron beam irradiation suggests that terminal sterilization may be possible, as opposed to the more costly scenario of aseptic manufacturing, which could enable significant cost savings.
Influenza vaccine stability, however, requires proper formulation. Influenza vaccine dried on a PDMS surface without a stabilizer lost essentially all of its activity after any storage period studied at 40°C. The optimized formulations studied here all provided significant stabilization of the vaccine, and the arginine/heptagluconate formulation maintained full vaccine activity at all of the conditions studied. It was interesting to note that the ratio of excipient concentration of the twofold combinations of stabilizers had no significant effect on stabilization, which provides additional formulation flexibility.
It is well known that trehalose and sucrose are good lyoprotectants [25, 28, [33] [34] [35] , and arginine, a basic amino acid, has been shown to both inhibit aggregation [29] and dry into an amorphous state [36] . Calcium heptagluconate has received limited attention as a stabilizer, but has been shown to stabilize hemoglobin in the liquid state [37] , which was the reason we included this excipient in our initial stabilizer screen. A possible reason for the success of multiplestabilizer formulations relative to formulations using single stabilizers (i.e., in chips, without the presence of additional formulation excipients used in the complete microneedle patch production) is the inhibition of crystallization of one excipient by the other excipient(s) [38] .
Some microneedle patches were made without a stabilizer in the first mold fill. These patches showed significantly less active vaccine after fabrication but did not have additional losses once dried and placed in storage. This indicates that the stabilizers included in the vaccine casting solution were needed predominately for stability during the fabrication process. Once the patches were completed, dried, and stored, the sucrose and PVA that compromise the bulk of the microneedles and backing provide sufficient stabilization to maintain vaccine activity during long-term storage. These findings of monovalent vaccine stability also held true for microneedle patches containing trivalent influenza vaccine. A dose comparable to the full human dose in clinical use was incorporated into these patches, which suggests that these As further tests of influenza vaccine stability in microneedle patches, patches utilizing the arginine/ heptagluconate formulation were subjected to very high temperature, freeze-thaw cycling, and electron beam irradiation. Over a period of 4 months, vaccine in microneedle patches lost no significant activity when stored at 60°C. While we do not envision patches needing to withstand such a high temperature for so long, it suggests that the microneedle patch could survive most any expected elevated thermal exposure that a seasonal influenza vaccine might experience during its 1-year shelf life. The excellent stability during freeze-thaw cycling suggests the ability of influenza vaccine in microneedle patches to survive freezing that could occur due to handling errors or faulty cold chain equipment. The ability of microneedle patches to preserve vaccine activity at both −80°C and after five consecutive freeze-thaw cycles could be associated with the relatively low moisture content of a few percent (data not shown). This small amount of water may be bound water that does not form ice crystals [39] or it may be phase-separated or otherwise in poor contact with the vaccine antigen, so that they do not interact.
Of relevance to the anticipated future use of microneedle patches for clinical influenza vaccination, maintenance of vaccine activity after exposure to sterilizing irradiation by electron beam suggests that terminal sterilization of microneedle patches could be used. This would avoid the high cost of aseptic manufacturing and therefore represent a significant cost savings. These findings, however, should be tempered by the fact that there is evidence that damaging effects of electron beam irradiation may not be apparent until after storage [40] (which we did not study) and that the sterilization cycle used in this study is expected to be suitable for Fig. 7 Stability of influenza vaccine in microneedle patches stored at 60°C with desiccant for up to 4 months compared to patches stored at 25°C under the same conditions. Monovalent microneedle patches were fabricated with A/Brisbane/10/2010 influenza vaccine formulated with a two-way combination of arginine and heptagluconate, each at a concentration of 5 % w/v in the vaccine casting solution. Data from patches stored at 60°C are shown, as well as control patches which were stored at 25°C and tested simultaneously. HA activity is shown as the percentage of active HA remaining in each patch. Data represent averages of n = 6 replicates, with standard deviation bars shown Fig. 8 Stability of influenza vaccine in microneedle patches subjected to five freeze-thaw cycles. Monovalent microneedle patches were fabricated with A/Brisbane/10/2010 influenza vaccine formulated with a two-way combination of arginine and heptagluconate each at a concentration of 5 % w/v in the vaccine casting solution. All samples were stored for a total of 24 h. Freeze-thawed samples were subjected to five freeze-thaw cycles each of 2 h at 4°C followed by 2 h at −20°C. Patches stored at 25°C served as the positive control to which all other HA levels were normalized. Patches were also stored at 4 and −80°C for comparison. Finally, liquid vaccine was subjected to the same freeze-thaw cycles. Data represent averages of n = 6 replicates, with standard deviation bars shown Fig. 9 Stability of influenza vaccine in microneedle patches exposed to electron beam irradiation. Monovalent microneedle patches were fabricated with A/Brisbane/10/2010 influenza vaccine formulated with a two-way combination of arginine and heptagluconate each at a concentration of 5 % w/v in the vaccine casting solution. HA activity is shown as the mass of active HA in each patch. Data represent averages of n = 6 replicates, with standard deviation bars shown microneedle patch sterilization, but sterility of these patches was not verified.
The primary test of vaccine activity in this work was performed by ELISA, which is a reasonable measure of vaccine stability, but is not the gold standard method, which is single radial immunodiffusion (SRID) [41] . We did not use SRID in this study because it is a complex assay that is difficult to operate reproducibly and has relatively low throughput. Instead, we verified our in vitro findings with in vivo studies of immunogenicity in mice. When compared to ID injection of a comparable vaccine dose, stored microneedle patches stored for more than 1 year at 25°C elicited an equal or stronger immune response after vaccination. This increase in antibody response when compared to ID delivery was seen in this study when using freshly made microneedle patch and has been noted before in the literature [20, 32] . To remove the effect of delivery route, stored microneedles were dissolved in water and injected ID. Mice receiving either fresh vaccine or stored vaccine delivered ID generated indistinguishable antibody responses, showing that the vaccine in the stored patches had retained its immunological activity.
When considered in the context of the broader microneedle patch literature, we believe this study further suggests that influenza vaccination using microneedle patches could be a valuable improvement over current vaccination practice. Previous studies indicate that vaccination using microneedle patches provides improved immune responses, probably due to targeting of the vaccine to the skin [42] . In addition, microneedle patches are small, which facilitates distribution and storage, and because they dissolve in the skin, microneedles generate no biohazardous sharp waste [9] [10] [11] [12] [13] [14] . In part because they are painless and can be self-administered, human subjects have indicated a strong preference for microneedle patches over hypodermic needle injections [18] . This study adds one more reason why influenza vaccination could benefit from microneedle patch administration; the remarkable thermostability demonstrated here suggests that influenza vaccine could be taken out of the cold chain to decrease costs, decrease vaccine spoilage, and increase convenience of vaccination.
Conclusion
This study shows that influenza vaccine formulated into microneedle patches remained stable after storage for 24 months at 25°C, storage for 4 months at 60°C, exposure to five freeze-thaw cycles, and irradiation during electron beam sterilization. Most stability measurements were made by assessing activity of monovalent vaccine by ELISA; additional studies using trivalent influenza vaccine assessed by ELISA and measuring antibody responses in mice gave similar results. A microneedle patch for influenza vaccination with this high level of stability could enable vaccine storage and distribution outside the cold chain to simplify and reduce costs of annual influenza vaccination campaigns and vaccine stockpiling for emergencies.
